These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29796999)

  • 1. This is a call to oncologists for action.
    Micó C; Berrocal A; Blasco A; Caballero C; Iranzo V; Lobo M; Camps C
    Clin Transl Oncol; 2018 Dec; 20(12):1493-1501. PubMed ID: 29796999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.
    Daroudi R; Mirzania M; Zendehdel K
    Int J Health Policy Manag; 2015 Oct; 5(2):99-105. PubMed ID: 26927395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.
    Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
    J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S34-S48. PubMed ID: 28535104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
    Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
    Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reality of economics for oncologists.
    Taylor D
    Breast; 2017 Jun; 33():183-190. PubMed ID: 28432979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do oncologists believe new cancer drugs offer good value?
    Nadler E; Eckert B; Neumann PJ
    Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center.
    Wilson L; Lin T; Wang L; Patel T; Tran D; Kim S; Dacey K; Yuen C; Kroon L; Brodowy B; Rodondi K
    J Manag Care Spec Pharm; 2017 Feb; 23(2):163-169. PubMed ID: 28125363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
    Del Paggio JC; Sullivan R; Schrag D; Hopman WM; Azariah B; Pramesh CS; Tannock IF; Booth CM
    Lancet Oncol; 2017 Jul; 18(7):887-894. PubMed ID: 28583794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seeking value as cancer drug costs soar.
    Bender E
    Cancer Discov; 2013 Aug; 3(8):833-4. PubMed ID: 23928760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 12. Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology.
    Sacristán JA; Lizan L; Comellas M; Garrido P; Avendaño C; Cruz-Hernández JJ; Espinosa J; Dilla T
    Adv Ther; 2016 Nov; 33(11):2059-2068. PubMed ID: 27718158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value and payment for oncology in the United States.
    Robinson JC
    Ann Pharm Fr; 2013 Sep; 71(5):285-90. PubMed ID: 24075699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of Anti-cancer Therapies with Reimbursement Limited to Comprehensive Cancer Centres Using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale].
    Büchler T; Melichar B; Vrána D; Lemstrová R; Fínek J; Dušek L; Petráková K; Prausová J
    Klin Onkol; 2017; 30(5):349-360. PubMed ID: 29031037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time.
    Saluja R; Arciero VS; Cheng S; McDonald E; Wong WWL; Cheung MC; Chan KKW
    J Oncol Pract; 2018 May; 14(5):e280-e294. PubMed ID: 29601250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can cancer care lead the way toward a value-based future?
    Macmillan K
    Am J Manag Care; 2019 Dec; 25(12 Spec No.):SP377-SP378. PubMed ID: 31860249
    [No Abstract]   [Full Text] [Related]  

  • 18. Perspectives on Cost and Value in Cancer Care.
    Saltz LB
    JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
    [No Abstract]   [Full Text] [Related]  

  • 19. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey.
    Schrag D; Hanger M
    J Clin Oncol; 2007 Jan; 25(2):233-7. PubMed ID: 17210946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs.
    Becker DJ; Lin D; Lee S; Levy BP; Makarov DV; Gold HT; Sherman S
    J Oncol Pract; 2017 Jul; 13(7):e653-e665. PubMed ID: 28493760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.